Mumbai: India’s largest drug maker, Ranbaxy, will have an exclusive six-month marketing opportunity to sell a generic version of Japanese drug maker Eisai’s drug for Alzheimer’s in the US.
The exclusivity status was confirmed by the US regulator, the Food and Drug Administration (FDA), after it dismissed Israeli drug major Teva’s claim for a shared marketing exclusivity for the drug, company officials said.
Ranbaxy may get the final FDA approval to market the drug known under the brand name, Aricept, as soon as patent protection over the drug expires on November 25.
Industry analysts estimate the drug will fetch Ranbaxy about $300 million (Rs. 1,370 crore) during the exclusivity period.
The company has not disclosed from which production facility it will supply the medicine, as two of its Indian manufacturing plants are yet to be cleared by the FDA for supply to that country.
Ranbaxy gets US nod to sell Alzheimer’s generic
